文献速递主动脉疾病

复杂主动脉瘤患者使用不同制造商混合匹配腔内移植物治疗的中期结局

Midterm Outcomes of Patients With Complex Aortic Aneurysms Treated Using Mixed and Matched Endoprosthesis From Different Manufacturers.
PubMed 文献 · J Endovasc Ther · 2024-09-26

本研究为两中心回顾性分析,评估2013至2023年间使用不同制造商腔内移植物组合行开窗/分支腔内主动脉修复(f/b-EVAR)的复杂主动脉瘤(cAA)患者结局。353例中80例(22.7%)需使用4家制造商移植物组合。中位随访400天,7例患者因内漏接受8次再干预,结论认为该策略安全且中期结果良好。

要点

  • 353例cAA患者中80例(22.7%)需使用不同制造商移植物组合完成f/b-EVAR。
  • 30天主要不良事件15例次(11例患者),包括3例(3.9%)死亡。
  • 中位随访400天,7例患者因内漏接受8次再干预。

核心结论

  • 在f/b-EVAR移植物近端和远端使用混合移植物治疗cAA患者是安全的,且中期结果良好。
  • 作者认为这一常用策略需通过精心设计的临床试验进一步探索,以提供基于可靠临床证据的指南。

研究设计与样本

  • 研究为两中心回顾性分析,数据来自前瞻性维护的数据库。
  • 纳入2013至2023年接受f/b-EVAR并使用不同制造商移植物组合的cAA患者。
  • 共353例cAA患者接受f/b-EVAR,其中80例(22.7%)使用了来自4家不同制造商的移植物组合。

主要发现

  • 80例中51例(64%)为胸腹主动脉瘤,29例(36%)为肾旁动脉瘤;74%为男性,中位年龄75(69,81)岁,动脉瘤大小65(59,72)mm。
  • 35例(44%)需要近端胸主动脉支架移植物:W.L. Gore 17例,Cook、Medtronic和Terumo各6例。
  • 77例(96%)需要分叉型装置,包括Cook Flex 34例、Gore 40例、Medtronic 3例;12例使用Gore髂动脉分支腔内移植物修复髂总动脉瘤。
  • 共植入154条分支:Gore 68条、Cook 82条、Medtronic 4条;共纳入314条靶血管。
  • 中位手术室时间209(186,278)分钟,估计失血量100(50,663)mL,透视时间77(59,100)分钟,剂量2385(1415,3885)mGy。

关键数值与推荐

  • 技术成功定义为装置植入后无I型或III型内漏或转为开放修复。
  • 主要终点包括技术成功、主要不良事件和再干预率;次要终点包括死亡率和中期装置性能。

临床怎么用

  • 原文结论认为,在f/b-EVAR移植物近端和远端使用混合装置治疗cAA患者是安全的,且中期结果良好。
  • 原文指出,该做法尚未在随机临床试验中正式评估,也未获美国食品药品监督管理局(FDA)认可,但在日常临床中广泛使用,结局记录不足。
  • 作者认为这一常用策略需通过精心设计的临床试验进一步探索,以提供基于可靠临床证据的指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate outcomes of patients with complex aortic aneurysms (cAAs) undergoing fenestrated/branched endovascular aortic aneurysm repair (f/b-EVAR) using a combination of endoprostheses from different manufacturers. METHODS: The study is a 2-center retrospective analysis of prospectively maintained databases of patients with cAAs undergoing f/b-EVAR using a combination of endoprostheses from different manufacturers from 2013 to 2023. Primary endpoints included technical success, major adverse events and reintervention rates. Technical success was defined as implantation of the device without type I or type III endoleak or conversion to open repair. Secondary endpoints included mortality and mid-term device performance. RESULTS: During this time, 353 patients with cAAs underwent f/b-EVARs at both centers. Of these, 80 (22.7%) required use of a combination of devices from 4 different manufacturers for repair. Fifty-one (64%) were treated for thoracoabdominal aortic aneurysms and 29 (36%) for pararenal aneurysms. Majority (74%) were male with a median age of 75 (69, 81) years and aneurysm size of 65 (59, 72) mm. Thirty-five (44%) patients required a proximal thoracic stent graft-W.L. Gore (17), Cook, Medtronic, and Terumo (6), respectively. Seventy-seven (96%) patients required a bifurcated device, including Cook Flex (34), Gore (40), and Medtronic (3). Twelve patients underwent common iliac artery aneurysm repair with a Gore iliac branched endoprosthesis. One hundred fifty-four limbs were implanted: Gore: 68, Cook: 82 and Medtronic: 4. Three hundred fourteen target vessels were incorporated. Median operating room time, estimated blood loss, fluoroscopy time and dose were 209 (186, 278) minutes, 100 (50, 663) mL, 77 (59, 100) minutes, 2385 (1415, 3885) mGy, respectively. Three endoleaks were observed on completion angiography-2 type Ic and 1 type IIIa-all of which resolved at 1 month. Fifteen MAEs were observed in 11 patients at 30 days, including 3 (3.9%) deaths, 7 renal insufficiency, 1 renal failure requiring dialysis, 2 MI and paraplegia, respectively. At a median follow-up of 400 (85, 1132) days, there were 8 reinterventions for endoleaks in 7 patients. CONCLUSIONS: The use of mixed devices proximal and distal to f/b-devices built to treat patients with cAAs is safe and has good mid-term results.Clinical ImpactWhile not yet formally assessed in randomized clinical trials or endorsed by the Food and Drug Administration (FDA), the practice of utilizing devices from various manufacturers to address complex aortic anatomy is widespread in everyday clinical settings, yet outcomes remain insufficiently documented. To our knowledge, ours is the first manuscript demonstrating that the use of endoprostheses from different manufacturers for treating patients with complex aortic aneurysms is both safe and yields favorable mid-term results. This frequently employed strategy warrants further exploration through meticulously designed clinical trials, aiming to furnish vascular specialists with a well-founded guideline based on robust clinical evidence.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Manunga J, Hanif H, Cravero E, et al. Midterm Outcomes of Patients With Complex Aortic Aneurysms Treated Using Mixed and Matched Endoprosthesis From Different Manufacturers. J Endovasc Ther. 2024. PMID: 39323323. doi:10.1177/15266028241283252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。